Connection

Chong Yu to Erlotinib Hydrochloride

Back to Details
This is a "connection" page, showing publications Chong Yu has written about Erlotinib Hydrochloride.
Chong Yu
Connection Strength
1.076
Erlotinib Hydrochloride
  1. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan. Cancer Med. 2017 Jul; 6(7):1563-1572.
    View in: PubMed
    Score: 0.686
  2. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. Eur J Cancer. 2019 09; 119:77-86.
    View in: PubMed
    Score: 0.199
  3. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896.
    View in: PubMed
    Score: 0.191
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.